Hospitals all around France are testing Withings ScanWatch to monitor Corona Virus patients’ right from their homes. This Smart Watch is still awaiting clearance from authorities and regulators but we can expect a launch by the end of this quarter.
Withings ScanWatch was announced by Withings at the start of this year during CES 2020 but it still hasn’t found its way into the market due to the necessary paperwork and not having the green signal to go ahead by the regulators. This Hybrid Smart Watch was under development for two years before being announced. The feature it was advertised for is its ability to track irregular rhythms in heart beats which can end up being a cause of anything from stroke to heart failure. The condition goes undiagnosed very often. Dizziness, fatigue and weakness are some of the symptoms of this condition which make it very vague to identify.
“ScanWatch is our most ambitious medical tracker and purposely designed to detect the early presence of AFib and sleep apnea – two related issues that are extremely common yet largely undiagnosed, despite their known impact on multiple health conditions,” stated Mathieu Letombe, few months ago. He is the Chief Executive Officer of Withings. “Worn throughout the day and night, ScanWatch provides an early warning system, collecting and sharing critical health data with users and their physicians.” He added.
ScanWatch can also detect Sleep Apnea. According to Withings, almost one in every eight people suffer from this condition around the world. It also has the ability to measure the level of oxygen present in blood stream. French hospitals are making use of all these features offered by this Smart Watch to monitor their COVID-19 patients remotely. Date collected from this will also benefit the researches going on right now. A market release by the end of first of 2020 is very much a possibility for Withings ScanWatch as of now with its two size variant available.
